Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

Medulloblastomas (MB) are the most common central nervous system malignancies in children. Numerous publications describe efforts to identify the predictive value of various patterns of MB pathology and immunohistochemistry, but received data appear to be controversial. Seventy-three patients with cerebellar MB were studied retrospectively. Tumor specimens were immunohistochemically examined with antibodies to various tumor-associated antigens. Also, apoptosis detection by the in situ end-labeling method was performed. Survival analysis was made using univariate and multivariate models. Tenascin immunoreactivity and apoptotic index (AI)>or=1.5% were found to be closely associated with poor prognosis according to an univariate analysis (P=0.008 and 0.003, respectively). The multivariate Cox proportional hazard model exhibited independent prognostic value for the apoptotic rate only (P=0.023). Tumors with tenascin expression and AI>or=1.5% significantly prevailed among MB with metastatic dissemination, whereas expression of c-erbB2 oncoprotein and epidermal growth factor receptor was found to be more typical for cases with local tumor recurrence. We came to the conclusion that tenascin immunoreactivity and AI were useful for individual MB prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Albright AL, Wisoff JH, Zeltzer PM et al. (1996) Effects of medulloblastoma resection on outcome in children: a report of Children's Cancer Group. Neurosurgery 38:265–271

    Article  PubMed  CAS  Google Scholar 

  2. David KM, Casey AT, Hayward RD et al. (1997) Medulloblastoma: is the 5-year survival improving? A review of 80 cases from a single institution. J Neurosurg 86:13–21

    Article  PubMed  CAS  Google Scholar 

  3. Merchant TE, Wang MH, Haida T et al. (1996) Medulloblastoma: long-term results for patients treated with definitive radiation therapy during the computed tomography era. Int J Radiat Oncol Biol Phys 36:29–35

    Article  PubMed  CAS  Google Scholar 

  4. Sure U, Berghorn WJ, Bertalanffy H et al. (1995) Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. Acta Neurochir (Wien) 132:59–65

    Article  CAS  Google Scholar 

  5. Bouffet E, Doz F, Demaille MC et al. (1998) Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse? Br J Cancer 77:1321–1326

    PubMed  CAS  Google Scholar 

  6. Bouffet E, Gentet JC, Doz F et al. (1994) Metastatic medulloblastoma: the experience of the French Cooperative M7 Group. Eur J Cancer 30A:1478–1483

    Article  PubMed  CAS  Google Scholar 

  7. Sure U, Bertalanffy H, Isenmann S et al. (1995) Secondary manifestation of medulloblastoma: metastases and local recurrences in 66 patients. Acta Neurochir (Wien) 136:117–126

    Article  CAS  Google Scholar 

  8. Chatty EM, Earle KM (1971) Medulloblastoma. A report of 201 cases with emphasis on the relationship of histologic variants to survival. Cancer 28:977–983

    Article  PubMed  CAS  Google Scholar 

  9. Gilbertson RJ, Jaros E, Perry RH et al. (1997) Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. Eur J Cancer 33:609–615

    Article  PubMed  CAS  Google Scholar 

  10. Mandel M, Toren A, Nativ O et al. (1993) DNA content—a prognostic factor in childhood medulloblastoma? Acta Oncol 32:691–692

    PubMed  CAS  Google Scholar 

  11. Schofield DE, Yunis EJ, Geyer JR et al. (1992) DNA content and other prognostic features in childhood medulloblastoma. Proposal of a scoring system. Cancer 69:1307–1314

    Article  PubMed  CAS  Google Scholar 

  12. Tait DM, Eeles RA, Carter R et al. (1993) Ploidy and proliferative index in medulloblastoma: useful prognostic factors? Eur J Cancer 29A:1383–1387

    Article  PubMed  CAS  Google Scholar 

  13. Tomita T, Yasue M, Engelhard HH et al. (1988) Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy. Cancer 61:744–749

    Article  PubMed  CAS  Google Scholar 

  14. Caputy AJ, McCullough DC, Manz HJ et al. (1987) A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 66:80–87

    Article  PubMed  CAS  Google Scholar 

  15. Coffin CM, Braun JT, Wick MR et al. (1990) A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 3:164–170

    PubMed  CAS  Google Scholar 

  16. Czerwionka M, Korf HW, Hoffmann O et al. (1989) Differentiation in medulloblastomas: correlation between the immunocytochemical demonstration of photoreceptor markers (S-antigen, rod-opsin) and the survival rate in 66 patients. Acta Neuropathol (Berl) 78:629–636

    Article  CAS  Google Scholar 

  17. Gilbertson RJ, Pearson AD, Perry RH et al. (1995) Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71:473–477

    PubMed  CAS  Google Scholar 

  18. Gilbertson RJ, Perry RH, Kelly PJ et al. (1997) Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57:3272–3280

    PubMed  CAS  Google Scholar 

  19. Goldberg-Stern H, Gadoth N, Stern S et al. (1991) The prognostic significance of glial fibrillary acidic protein staining in medulloblastoma. Cancer 68:568–573

    Article  PubMed  CAS  Google Scholar 

  20. Herms JW, Behnke J, Bergmann M et al. (1997) Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 19:510–515

    Article  PubMed  CAS  Google Scholar 

  21. Jaros E, Lunec J, Perry RH et al. (1993) p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 68:801–807

    PubMed  CAS  Google Scholar 

  22. Moriuchi S, Shimizu K, Miyao Y et al. (1996) An immunohistochemical analysis of medulloblastoma and PNET with emphasis on N-myc protein expression. Anticancer Res 16:2687–2692

    PubMed  CAS  Google Scholar 

  23. Sawa H, Takeshita I, Kuramitsu M et al. (1986) Neuronal and glial proteins in medulloblastomas. I. Immunohistochemical study. Anticancer Res 6:905–909

    PubMed  CAS  Google Scholar 

  24. Batra SK, McLendon RE, Koo JS et al. (1995) Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 24:39–45

    Article  PubMed  CAS  Google Scholar 

  25. Goumnerova LC (1996) Growth factor receptors in medulloblastoma. J Neurooncol 29:85–89

    Article  PubMed  CAS  Google Scholar 

  26. Segal RA, Goumnerova LC, Kwon YK et al. (1994) Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 91:12867–12871

    Article  PubMed  CAS  Google Scholar 

  27. Laurent JP, Chang CH, Cohen ME (1985) A classification system for primitive neuroectidermal tumors (medulloblastoma) of the posterior cranial fossa. Cancer 56 (Suppl):1807–1809

    Article  PubMed  CAS  Google Scholar 

  28. Miyagami M, Satoh K, Tsubokawa T (1993) A long-surviving case of recurrent medulloblastoma displaying effectiveness of ACNU/vincristine chemotherapy. J Neurooncol 18:41–47

    Article  Google Scholar 

  29. Weiner H (1995) The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 37:179–194

    Article  PubMed  CAS  Google Scholar 

  30. Chiquet-Ehrismann R (1993) Tenascin and other adhesion modulating proteins in cancers. Semin Cancer Biol 4:301–310

    PubMed  CAS  Google Scholar 

  31. Castellani P, Dorcaratto A et al. (1995) Tenascin distribution in human brain tumours. Acta Neurochir (Wien) 136:44–50

    Article  CAS  Google Scholar 

  32. Higuchi M, Ohnishi T, Arita N et al. (1993) Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol (Berl) 85:481–487

    CAS  Google Scholar 

  33. Jahkola T, Toivonen T, von Smitten K et al. (1996) Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 69:445–447

    Article  PubMed  CAS  Google Scholar 

  34. Ishihara A, Yatani R, Sakakura T (1993) Relationship of an extracellular matrix protein, tenascin and breast diseases (in Japanese). Rinsho Byori 41:1099–1107

    PubMed  CAS  Google Scholar 

  35. Kusagawa H, Onoda K, Namikawa S et al. (1998) Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer 77:98–102

    PubMed  CAS  Google Scholar 

  36. Glinsky GV, Glinsky VV, Ivanova AB et al. (1997) Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 115:185–193

    Article  PubMed  CAS  Google Scholar 

  37. McConkey DJ, Greene G, Pettaway CA (1996) Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56:5594–5599

    PubMed  CAS  Google Scholar 

  38. Yawata A, Adachi M, Okuda H et al. (1998) Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene 16:2681–2686

    Article  PubMed  CAS  Google Scholar 

  39. Berardo MD, Elledge RM, de Moor C et al. (1998) bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82:1296–1302

    Article  PubMed  CAS  Google Scholar 

  40. Zhang GJ, Kimijima I, Watanabe T et al. (1998) Correlation between apoptotic index, bcl-2 protein expression and progression and prognosis in breast carcinoma (in Japanese). Gan To Kagaku Ryoho 25 Suppl 3:415–421

    PubMed  Google Scholar 

  41. Komaki R, Fujii T, Perkins P et al. (1996) Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 36:601–605

    Article  PubMed  CAS  Google Scholar 

  42. Yamasaki F, Tokunaga O, Sugimori H (1997) Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 66:439–448

    Article  PubMed  CAS  Google Scholar 

  43. Matsuda H, Strebel FR, Kaneko T et al. (1996) Apoptosis and necrosis occurring during different stages of primary and metastatic tumor growth of a rat mammary adenocarcinoma. Anticancer Res 16:1117–1121

    PubMed  CAS  Google Scholar 

  44. Kaufmann AM, Lichtner RB, Schirrmacher V et al. (1996) Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Oncogene 13:2349–2358

    PubMed  CAS  Google Scholar 

  45. Steeg PC, Cohn KH, Leone A (1991) Tumor metastasis and nm23: current concepts. Cancer Cells 3:257–262

    PubMed  CAS  Google Scholar 

  46. Charpin C, Bouvier C, Garcia S et al. (1997) Automated and quantitative immunocytochemical assays of Nm23/NDPK protein in breast carcinomas. Int J Cancer 74:416–420

    Article  PubMed  CAS  Google Scholar 

  47. Duenas-Gonzalez A, Abad-Hernandez MM, Garcia-Mata J et al. (1996) Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinico-pathological findings. Cancer Lett 101:136–142

    Google Scholar 

  48. Kapranos N, Karaiossifidi H, Kouri E et al. (1996) Nm23 expression in breast ductal carcinomas: a ten-year follow-up study in a uniform group of node-negative breast cancer patients. Anticancer Res 16:3987–3990

    PubMed  CAS  Google Scholar 

  49. Easty DJ, Maung K, Lascu I et al. (1996) Expression of NM23 in human melanoma progression and metastasis. Br J Cancer 74:109–114

    PubMed  CAS  Google Scholar 

  50. Gazzeri S, Brambilla E, Negoescu A et al. (1996) Overexpression of nucleoside diphosphate kinase A/nm23-H1 protein in human lung tumors: association with tumor progression in squamous carcinoma. Lab Invest 74:158–167

    PubMed  CAS  Google Scholar 

  51. Lindmark G (1996) NM-23 H1 immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer. Br J Cancer 74:1413–1418

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropathology, Neurosurgical NN Burdenko Institute, Fadeeva str. 5, 125 047, Moscow, Russia

    Andrey Korshunov & Regina Sycheva

  2. Department of Neuro-oncological Surgery, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Golanov

  3. Department of Pediatric Neurooncology, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Sergey Ozerov

Authors
  1. Andrey Korshunov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrey Golanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sergey Ozerov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Regina Sycheva
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korshunov, A., Golanov, A., Ozerov, S. et al. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 16, 37–44 (1999). https://doi.org/10.1007/BF02478900

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02478900

Key words

Search

Navigation